RUA BIOSCIENCE LIMITED |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.069 NZD | -1.43% |
|
0.00% | -42.50% |
| Apr. 15 | Rua Bioscience to Expand Compassionate Access Program at Tairāwhiti | MT |
| Apr. 04 | New Zealand Shares Flat on as Rate Cut Hopes Dim; Rua Bioscience Signs Cannabis Supply Deal | MT |
| Sales 2022 | 645K 384K | Sales 2023 | 668K 398K | Capitalization | 24.35M 14.48M |
|---|---|---|---|---|---|
| Net income 2022 | -8M -4.76M | Net income 2023 | -5M -2.97M | EV / Sales 2022 | 62.5 x |
| Net cash position 2022 | 9.11M 5.42M | Net cash position 2023 | 4.45M 2.64M | EV / Sales 2023 | 29.8 x |
| P/E ratio 2022 |
-5.5
x | P/E ratio 2023 |
-3.85
x | Employees | - |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 51.93% |
More Fundamentals
* Assessed data
More news
| 1 day | -1.43% | ||
| Current month | -11.54% | ||
| 1 month | -6.76% | ||
| 3 months | -29.59% | ||
| 6 months | -35.51% | ||
| Current year | -42.50% |
1 week
0.07
0.07
1 month
0.070.08
Current year
0.070.12
1 year
0.070.20
3 years
0.070.53
5 years
0.070.75
10 years
0.070.75
| Managers | Title | Age | Since |
|---|---|---|---|
Paul Naske
CEO | Chief Executive Officer | - | 19-01-31 |
Manu Caddie
FOU | Founder | - | 15-12-31 |
Liam Walker
DFI | Director of Finance/CFO | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Anthony Barclay
BRD | Director/Board Member | - | 23-04-30 |
Anna Stove
CHM | Chairman | - | 19-04-30 |
| Director/Board Member | - | 22-07-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-24 | 0.069 | -1.43% | 16,777 |
| 24-04-23 | 0.07 | +1.45% | 19,809 |
| 24-04-22 | 0.069 | +1.47% | 23,646 |
| 24-04-19 | 0.068 | -4.23% | 7,943 |
| 24-04-18 | 0.071 | +2.90% | 51,828 |
End-of-day quote New Zealand S.E., April 23, 2024
More quotes
Rua Bioscience Limited is a New Zealand-based medicinal cannabis company. The Company is engaged in the business of research and development, and pharmaceutical distribution and marketing. The Company is focused on breeding, cultivating, manufacturing, and supplying medicinal cannabis. The Company operates through one segment: research and development and the sale of pharmaceutical products in Germany and New Zealand. The Company also operates a full research laboratory in Gisborne, which enables cannabinoid testing, microscopic analysis, moisture analysis, sample preparation and extraction, solvent removal, viscosity measurements, and impurity testing.
Sector
Pharmaceuticals
Calendar
2024-08-25
- Q4 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -42.50% | 6.46M | |
| +37.37% | 6.05B | |
| -15.69% | 4.45B | |
| -12.46% | 3.06B | |
| -0.12% | 3.04B | |
| +0.47% | 2.58B | |
| +36.06% | 1.79B | |
| +0.84% | 1.66B | |
| -10.60% | 1.63B | |
| -12.03% | 1.54B |
- Stock Market
- Equities
- RUA Stock
